Occupational Therapists in Austin, MN Accepting Medicare
6 Occupational Therapists found. Showing 1 - 6
 Kathleen Byram Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1999 |
Patricia Marie Lienau, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 6th Ave Sw, Austin, MN 55912 Phone: 507-433-9006 |
Ms. Kristi J Hyland, COTA Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 1st Ave Nw, Austin, MN 55912 Phone: 507-434-1999 |
Anne Koch Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 24101 547th Ave, Austin, MN 55912 Phone: 763-689-5385 |
Carol Davis Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 700 1st Dr Nw, Austin, MN 55912 Phone: 763-689-5385 |
Miss Samantha Jo Plaehn, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1270 |
News Archive
New book shows couples how to lose weight and stay healthy
After analyzing thousands of hours of video recordings of married couples talking with each other about their health, two UCLA psychology professors were shocked by what they saw.
Potential new COVID vaccine from Australia
Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.
Scientists discover promising potential drug target for cystic fibrosis
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis.
MSU professor focuses on new formulation for old drug to treat parasitic diseases
With the help of another $2 million in funding from the Bill & Melinda Gates Foundation, researchers are moving closer to setting up human clinical trials for a reformulated drug that could be the linchpin of treatment efforts against two debilitating tropical diseases.
NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD
The winner of the 2009 EUROPEAN BIOTECHNICA AWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receives the lion's share of the €100,000 prize money, which is awarded each year by Deutsche Messe AG and its partners. The aim of the award is to celebrate the achievements of innovative European companies in the field of biotechnology and the life sciences.
› Verified 3 days ago
Chiropractors
Physical Therapists
Optometrists
Occupational Therapists
Speech-Language Pathologists
Podiatrists
Audiologists